Merck patent on Bridion affirmed through 2026

• A federal court in New Jersey Tuesday found in favor of Merck (NYSE:MRK) in a patent case that involved a patent term extension for the company's muscle relaxant reversal agent Bridion (sugammadex).
• The ruling means that the main Bridion patent is valid through at least January 2026.

More on Merck

• Merck's Strength Is Nothing To Be Afraid Of

• Merck Is Climbing Higher, With Growth Potential

• Merck: Solid Pharma Buy With Strong Upside If Keytruda Patents Extended